Company: TVRD
Filing Date: 2025-02-14
Form Type: S-4/A
Source: 0001104659-25-013053
Chunk: 924

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-02-14
Form: S-4/A
Chunk 924
---
 
 ​ | For the Year EndedDecember 31, 
 2023                           |   |        |   | ​ | ​ | 2022 |   |        |   | ​ 
 ​ |
|:------------------------------------------|:--|:--|:-------------------------------|:--|-------:|:--|:--|:--|:-----|:--|-------:|:--|:--|
| Income tax at U.S. federal statutory rate | ​ | ​ | ​                              | $ | -3,643 | ​ | ​ | ​ | ​    | $ | -4,314 | ​ | ​ |
| State taxes, net of federal benefit       | ​ | ​ | ​                              | ​ |      — | ​ | ​ | ​ | ​    | ​ |      — | ​ | ​ |
| Valuation allowance                       | ​ | ​ | ​                              | ​ |  3,604 | ​ | ​ | ​ | ​    | ​ |  4,312 | ​ | ​ |
| Other                                     | ​ | ​ | ​                              | ​ |     39 | ​ | ​ | ​ | ​    | ​ |      2 | ​ | ​ |
| Total income tax                          | ​ | ​ | ​                              | $ |      — | ​ | ​ | ​ | ​    | $ |      — | ​ | ​ |

The Company’s significant components of deferred tax assets are as follows (in thousands):

| ​                                                  
 ​                                                  | ​ 
 ​ | ​ 
 ​ | December 31, 
 2023         |   |         |   | ​ | ​ | 2022 |   |        |   | ​ 
 ​ |
|:---------------------------------------------------|:--|:--|:-------------|:--|--------:|:--|:--|:--|:-----|:--|-------:|:--|:--|
| Federal net operating loss carryforwards           | ​ | ​ | ​            | $ |   7,235 | ​ | ​ | ​ | ​    | $ |  5,882 | ​ | ​ |
| Capitalized research and development expense       | ​ | ​ | ​            | ​ |   5,665 | ​ | ​ | ​ | ​    | ​ |  3,470 | ​ | ​ |
| Tax credits                                        | ​ | ​ | ​            | ​ |     417 | ​ | ​ | ​ | ​    |